Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant
J.F.R. Robertson, A. Howell, V.A. Gorbunova, T. Watanabe, T. Pienkowski, M.R. LichinitserVolume:
92
Language:
english
Pages:
6
DOI:
10.1007/s10549-004-4776-0
Date:
July, 2005
File:
PDF, 188 KB
english, 2005